Dr Gerhardt Attard is a clinician scientist and consultant medical oncologist at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London.
In December 2015, he became Team Leader of the Treatment Resistance Group in the Centre for Evolution and Cancer in the ICR.
He graduated with a degree in medicine from the University of Malta in 1999, was awarded membership of the Royal College of Physicians in 2002 and after a fellowship in drug development in 2003/04, obtained a PhD in Medicine from the University of London in 2009.
He specialised in medical oncology as a National Institute for Health Research academic clinical lecturer in The Royal Marsden between 2009 and 2013 and was appointed a consultant in the urology unit in The Royal Marsden in April 2013. He was awarded a Cancer Research UK clinician scientist fellowship in 2012 and an advanced fellowship in 2016.
His main research interest is the development of novel therapeutics and biomarkers for metastatic prostate cancer. His group recently used plasma DNA analyses to show that AR gene aberrations associate with resistance to hormonal therapies for CRPC.
He is a co-author of more than 110 peer-reviewed manuscripts and has published several important papers on advanced prostate cancer. Dr Attard’s many awards over the years include the ASCO Foundation Annual Merit Award in 2007, Prostate Cancer Foundation Young Investor Award in 2008, the AACR-GlaxoSmithKline Outstanding Clinical Scholar Award in 2009, the Medical Research Society/Academy of Medical Sciences Sue McCarthy Prize in 2010 and the McElwain award in 2010.
Dr Attard sits on a number of advisory boards and is the Associate Editor for Genitourinary Cancers on the Annals of Oncology editorial board. He is chief investigator for several international and national clinical trials and is a comparison lead investigator in the STAMPEDE clinical trial. He co-leads the PCF-SELECT and STRATOSPHere consortia.